Pacific Edge FY2024 Operating Revenue Jumps 22% to NZ$23.9 Million, Total Revenue Rises 12% to NZ$29.3 Million
Cancer diagnostics company Pacific Edge (NZE:PEB, ASX:PEB) said operating revenue rose 22% to NZ$23.9 million and total revenue increased 12% to NZ$29.3 million for the year ended March, according to
Pacific Edge Revenues Up, Cash Costs Down on Reorganisation
Cancer diagnostic pharmaceutical company Pacific Edge Ltd (ASX:PEB) has reported a drop of 24 percent in cash costs in the second half of the Financial Year, based on a reorganisation of the company, in addition to revenue growth throughout the year ahead of its chairman Chris Gallaher stepping down.
Pacific Edge Ltd: Cash Burn Slows Coverage Catalysts in Focus
Pacific Edge Reports Steady Growth in Bladder Cancer Test Volumes in Fiscal Q4
Pacific Edge's (ASX:PEB, NZE:PEB) test volumes for its Cxbladder product rose 0.4% to 7,210 in the fiscal fourth quarter ended March 31, compared with the prior three-month period, the cancer diagnost
New Zealand Shares Flat on Thursday; Pacific Edge's Chair to Retire
New Zealand shares were flat with a negative bias at Thursday's close, dragged down by the shares of firms in the heavyweight finance sector. The S&P/NZX 50 Index was little changed to close at 11,808
Pacific Edge Ltd.: Chair Chris Gallagher and Non-Exec Director Mark Green Retire From Bd.
Pacific Edge Ltd.: Chair Chris Gallagher and Non-Exec Director Mark Green Retire From Bd.
New Zealand Shares Flat on Monday; Genesis Minerals Secures Financial Close for Lauriston Solar Farm
New Zealand shares were flat with a positive bias on Monday's close as gains from shares of consumer non-durable firms and industrial services firms were offset by losses from shares of firms in the n
Pacific Edge's Test Volume Declines Nearly 8% in Fiscal Q3; Shares Fall 3%
Pacific Edge (NZE:PEB) processed 7,172 tests in the fiscal third quarter ended Dec. 31, 2023, 7.7% lower than the 7,768 tests processed in the same quarter a year prior, according to a Monday report.
New Zealand Shares End the Year Flat Following a Two-Day Rally; Me Today to Undertake Share Consolidation
New Zealand shares ended the year flat with positive bias during a shortened trading day Friday following a two-day rally as investors stood their ground ahead of the new year. The S&P/NZX 50 index ch
New Zealand Shares Post Back-to-Back Gains on Rate Cut Hopes
New Zealand shares rose for the second session in a row on Thursday on renewed optimism over interest rate cuts. The S&P/NZX 50 Index jumped 0.77%, or 90.25 points, to close at 11,768.68. Investors in
New Zealand Shares Rise on Strong Trading in Services Sector
New Zealand shares rose on Wednesday as most sectors saw gains, particularly in services. The S&P/NZX 50 gained 0.38%, or 44 points, to close at 11,678.43. Gainers beat losers with the distribution se
Pacific Edge Plans Coordinated Response to US FDA Proposal to Regulate Lab-Developed Tests
Pacific Edge (ASX:PEB, NZX:PEB) is opposing the US Food and Drug Administration's proposal to regulate laboratory-developed tests (LDTs) as medical devices in the country. In a Monday disclosure, the
Pacific Edge [ASX:PEB] Shares Collapse After FDA Snub - Money Morning Australia
Pacific Edge Celebrates Extension of Novitas LCD Stay
Pacific Edge (ASX:PEB, NZE:PEB) expressed appreciation for the recent decision made by Novitas and First Coast to postpone the implementation of the local coverage determination (LCD) issued in early June, the cancer diagnostics company said Thursday.
Stocks of the Hour: Morella Corporation, Pacific Edge, Critical Resources
Morella Corporation (ASX:1MC) has released results from drilling at the Mallina Project in WA, which is a joint venture between Morella and Sayona Mining (ASX:SYA). The mineralised strike has been ext
Pacific Edge [ASX:PEB] Ups Cancer Tests in Q4 and Hits New Record - Money Morning Australia
Pacific Edge (ASX:PEB) Completes Agreement With Te Whatu Ora Southern
No Data